 Mind Medicine Inc. MNMD, -7.06 MindMed shares rose 10 in premarket trades on Thursday after the company said patient dosing in its Phase 2b trial is ongoing and offers a highly attractive commercial opportunity. The clinical stage biopharmaceutical company thats developing psychedelic medicine to treat brain health disorders said a manuscript that expands on previously reported positive data has been published in the peer-reviewed scientific journal, Biological Psychiatry. 